Radius Health, Inc.

( )
RDUS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 0.25%244.421.3%$797.86m
IMMUImmunomedics, Inc. 0.00%85.3611.0%$697.18m
MRNAModerna, Inc. 0.99%70.160.0%$673.11m
NVAXNovavax, Inc. 1.71%115.5096.5%$639.75m
ILMNIllumina, Inc. 1.69%304.963.5%$592.64m
GILDGilead Sciences, Inc. 0.56%62.601.0%$577.34m
REGNRegeneron Pharmaceuticals, Inc. 0.00%574.062.7%$443.39m
VRTXVertex Pharmaceuticals, Inc. 0.00%268.181.9%$340.86m
BIIBBiogen, Inc. 0.00%273.281.6%$334.97m
ALXNAlexion Pharmaceuticals, Inc. 2.06%116.792.0%$291.10m
EXASEXACT Sciences Corp. 1.83%99.4920.7%$262.00m
SRNESorrento Therapeutics, Inc. 2.13%9.841.5%$245.99m
VXRTVaxart, Inc. 3.24%7.640.0%$220.82m
SGENSeattle Genetics, Inc. 0.00%184.956.0%$212.14m
MNTAMomenta Pharmaceuticals, Inc. 0.00%52.403.0%$193.58m

Company Profile

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.